Fred Hutchinson Cancer Research Center’s latest findings will be featured in about 50 presentations at the annual meeting of the American Association for Cancer Research, “Driving Innovative Cancer Science to Patient Care,” to be held April 14-18 in Chicago.
This year’s AACR annual meeting puts a spotlight on Hutch researchers working on next-gen approaches to transgenic T-cell receptor, or TCR, immunotherapy, in which patients’ T cells are genetically engineered to produce a naturally occurring, cancer-targeting receptor called a TCR.
Presentation topics include:
- Next-generation T-cell therapies
- Big-data for cancer Research
- Racial disparities in prostate cancer
- Cancer survivorship
- Precision medicine
More information about this year's meeting is available in our press release.
Stories from AACR
Immunotherapy strategy for ovarian cancer aims to rewire a ‘kill switch’ to ramp-up signal
T cells bearing a new engineered protein boost immunotherapy’s effectiveness in laboratory models of AML, ovarian, pancreatic cancers
April 16, 2018 in Hutch News
T cells bearing a new engineered protein boost immunotherapy’s effectiveness in laboratory models of AML, ovarian, pancreatic cancers
April 16, 2018 in Hutch News
How does leukemia escape from immunotherapy?
New tech enables deep dive into mysterious results, sets stage for future improvements
April 16, 2018 in Hutch News
New tech enables deep dive into mysterious results, sets stage for future improvements
April 16, 2018 in Hutch News
Fred Hutch scientists to feature next-generation T-cell therapies, big data, precision medicine and more at AACR
The American Association for Cancer Research will hold its 111th annual meeting April 14-18 in Chicago
April 10, 2018 in News Releases
The American Association for Cancer Research will hold its 111th annual meeting April 14-18 in Chicago
April 10, 2018 in News Releases
Should prostate cancer screening be different for black men?
New study confirms prostate cancer is more common and more deadly in African-Americans
April 23, 2017 in Hutch News
New study confirms prostate cancer is more common and more deadly in African-Americans
April 23, 2017 in Hutch News
Immunotherapy for ovarian cancer shows promise in mouse model, but hurdles remain
‘Tumor microenvironment’ poses unique challenges for T-cell therapy in solid tumors
April 4, 2017 in Hutch News
‘Tumor microenvironment’ poses unique challenges for T-cell therapy in solid tumors
April 4, 2017 in Hutch News
Finding ways to deliver on the promise of precision oncology
‘Functional genomics’ method aims to marry three powerful techniques to speed personalized cancer treatments to patients
March 31, 2017 in Hutch News
‘Functional genomics’ method aims to marry three powerful techniques to speed personalized cancer treatments to patients
March 31, 2017 in Hutch News
Immunotherapy shows promise in preventing leukemia relapse
Group of 12 high-risk patients who received engineered T cells after bone marrow transplant still in remission after more than two years
Dec. 5, 2016 in Hutch News
Group of 12 high-risk patients who received engineered T cells after bone marrow transplant still in remission after more than two years
Dec. 5, 2016 in Hutch News
Progress in ‘precision prevention’ for colorectal cancer
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors
April 18, 2016 in Hutch News
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors
April 18, 2016 in Hutch News
FOR THE MEDIA
Hutch Team
For more information or to arrange an interview, please contact Molly McElroy at 206.667.6651 or email our media relations team.
ACCESS INFORMATION OR DOWNLOAD HIGH-RES PHOTOS AND VIDEO
